Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was founded in 1995 and is headquartered in Watertown, Massachusetts, USA, with 113 full-time employees. It is a biopharmaceutical company focusing on the research and development of small molecule drugs for the treatment of viral infections and liver diseases .
Enanta Pharmaceuticals, Inc. (ENTA):
Enanta Pharmaceuticals is a R&D-focused biotechnology company that uses its powerful chemical-driven methods and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development are currently focused on the following disease targets: hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH)/PBC and respiratory syncytial virus (RSV).
By Enanta Pharmaceuticals AbbVie discovery and development of cooperation of two protease inhibitors and paritaprevir glecaprevir now FDA approved antiviral portion (DAA) scheme act directly AbbVie, in the United States MAVYRET TM (glecaprevir / pibrentasvir) and VIEKIRA PAK ( Paritaprevir / ritonavir / ombitasvir / dasabuvir) is sold for the treatment of hepatitis C virus (HCV) infection.
Enanta Pharmaceuticals, Inc. and Abbott Laboratories signed a collaborative development and licensing agreement to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta’s wholly-owned product line includes EDP-305, which is an FXR agonist candidate for NASH and PBC; and EDP-938, an N-protein inhibitor for RSV. Enanta is also developing early product candidates for HBV.